Targeting ALK: Precision Medicine Takes on Drug Resistance.
Targeting ALK: Precision Medicine Takes on Drug Resistance.
复制标题
DOI：
10.1158/2159-8290.cd-16-1123
复制
发表时间：
2017-02
期刊：
影响因子：
28.2
通讯作者：
Shaw AT
中科院分区：
文献类型：
--
作者：
Lin JJ;Riely GJ;Shaw AT
间变性淋巴瘤激酶（ALK）是几种ALK重排恶性肿瘤（包括非小细胞肺癌（NSCLC））中经过验证的分子靶点。然而，使用酪氨酸激酶抑制剂（TKI）靶向ALK的临床获益几乎普遍受到耐药性出现的限制。现已发现ALK TKI耐药的多种机制，这些基本机制为开发新的治疗策略以克服临床耐药提供了信息。在这篇综述中，我们总结了目前针对ALK的成功和挑战。
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, including non-small-cell lung cancer (NSCLC). However, the clinical benefit of targeting ALK using tyrosine kinase inhibitors (TKIs) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this Review, we summarize the current successes and challenges of targeting ALK.